Recent studies have demonstrated that miR-30d prevents pathological cardiac hypertrophy via negatively regulating its target genes MAP4K4 and GRP78 and inhibiting the prohypertrophic nuclear factor of activated T cells[10]. The gene discussed is MAP4K4; the disease is cardiac hypertrophy.